21 completed, 13 recruiting, 9 terminated, 6 active not recruiting. 27 Phase 3, 8 Phase 2, 6 Phase 1, 5 Phase 4.
Follow ravulizumab: new trials by email Literature Review of ravulizumab trials Research Report on ravulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders Ravulizumab - Preeclampsia | Phase 2 | Recruiting | Mayo Clinic | 14 | 2027-04-01 | 2026-10-22 |
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2026-07-27 | 2026-10-21 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| Ravulizumab Outcomes in Polish Patients With aHUS Ravulizumab - Atypical Hemolytic Uremic Syndrome | Recruiting | AstraZeneca | 80 | 2026-06-24 | 2026-09-15 | |
| A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone - Generalized Myasthenia Gravis, gMG | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2026-03-04 | 2026-04-09 |
| Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data Danicopan, Soliris/Ultomiris - Paroxysmal Nocturnal Hemoglobinuria, PNH | Active not recruiting | Alexion Pharmaceuticals, Inc. | 50 | 2026-01-14 | 2026-02-17 | |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis Ravulizumab - Generalized Myasthenia Gravis, Anti-AChR Antibody Positive | Recruiting | Alexion Pharmaceuticals, Inc. | 40 | 2025-07-31 | 2026-02-05 | |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation Ravulizumab, Placebo - Delayed Graft Function, DGF | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 450 | 2025-05-19 | 2026-06-18 |
| Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis Ravulizumab - Myasthenia Gravis, Generalized | Recruiting | AstraZeneca | 50 | 2025-05-15 | 2026-09-16 | |
| Real-life Treatment Outcomes of Ravulizumab in PNH Ravulizumab - Paroxysmal Nocturnal Haemoglobinuria | Active not recruiting | AstraZeneca | 64 | 2025-02-06 | 2026-09-23 | |
| Study of Ultomiris® (Ravulizumab) Safety in Pregnancy Ultomiris - Ultomiris-exposed Pregnant/ Postpartum, Pregnancy | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2024-12-16 | 2026-04-16 | |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2024-10-10 | 2026-06-05 |
| Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder Ravulizumab - Neuromyelitis Optica | Recruiting | University of Texas Southwestern Medical Center | 35 | 2024-07-10 | 2026-10-13 | |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2023-06-24 | 2026-04-17 |
| ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE Placebo, Ravulizumab - Chronic Kidney Disease, CKD | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 555 | 2023-04-06 | 2026-07-22 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
Showing 20 of 51. Sign in to see all of them.
Hemoglobinuria, Paroxysmal (17) · Myasthenia Gravis (7) · Atypical Hemolytic Uremic Syndrome (5) · Neuromyelitis Optica (5) · Thrombotic Microangiopathies (4) · COVID-19 (3) · Glomerulonephritis, IGA (3) · Acute Kidney Injury (2) · Proteinuria (2) · Renal Insufficiency, Chronic (2) · Acute Lung Injury (1) · Adrenal Insufficiency (1) · Amyotrophic Lateral Sclerosis (1) · Anemia (1) · Delayed Graft Function (1)
Alexion Pharmaceuticals, Inc. (38) · AstraZeneca (3) · BioCryst Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · Brigham and Women's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Novartis Pharmaceuticals (1) · University of Texas Southwestern Medical Center (1)
United States (31) · United Kingdom (28) · Italy (26) · Spain (23) · France (21) · Japan (21) · South Korea (21) · Germany (19) · Canada (17) · Australia (14) · Poland (12) · Taiwan (12) · Netherlands (11) · Brazil (10) · China (9)
Austin G Kulasekararaj, MBBS, MD (1) · Darin T. Okuda, MD (1) · Frances Hall Hall, FRCP (UK), D.Phil (1) · Maria Lourdes Gonzalez Suarez, MD, PhD (1) · Morag Griffin, MBChB (1) · Peter Sguigna, MD (1) · Philippe-Antoine Bilodeau, MD (1) · Sydney Williams (1) · Tolga Baykal, MD, PhD (1)
PMID 33783815, PMID 34473343, PMID 34526067, PMID 39455063, PMID 30171081, PMID 31949012, PMID 32299680, PMID 32554923, PMID 32641154, PMID 32660611, PMID 32869125, PMID 33048203, PMID 33178408, PMID 33407224, PMID 33826106, PMID 34169200, PMID 36272026, PMID 36329366, PMID 36852670, PMID 36890354, PMID 36958364, PMID 37094330, PMID 37103755, PMID 37528520, PMID 37695623, PMID 37804344, PMID 37977159, PMID 38319212, PMID 38356884, PMID 38477987, PMID 38551806, PMID 39105067, PMID 39468592, PMID 39841198, PMID 40447351, PMID 40448185, PMID 40694294, PMID 41566054, PMID 41782198, PMID 42384439, PMID 42441931, PMID 42853533
2016 (5), 2019 (4), 2017 (3), 2015 (2), 2014 (1), 2018 (1), 2023 (1)